74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Organon & Co
Open
SectorHealthcare
12.94 1.81
Overview
Share price change
24h
Min
12.25
Max
12.98
Income | -250M 109M |
|---|---|
Sales | 10M 1.6B |
P/E Sector Avg | 3.192 57.333 |
EPS | 0.9 |
Dividend yield | 10.54 |
Profit margin | 6.847 |
Employees | 10,000 |
EBITDA | -64M 338M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +37.7% upside |
Dividend yield Sector Avg | 10.54% 2.63% |
|---|---|
Next Earnings | 1 May 2025 |
Next Dividend date | 12 Jun 2025 |
Next Ex Dividend date | 9 May 2025 |
Market Cap | -1.2B 2.9B |
|---|---|
Previous open | 11.13 |
Previous close | 12.94 |
Technical Score
By Trading Central
Confidence
Very Strong Bullish Evidence
Organon & Co Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Organon & Co Forecast
Price Target
By TipRanks
37.7% upside
12 Months Forecast
Average 16.8 USD 37.7%
High 24 USD
Low 11 USD
Based on 5 Wall Street analysts offering 12 month price targets forOrganon & Co - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Organon & Co
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.
